OBJECTIVE: To study the predictive value of functional and biologic metrics for predicting radiation pneumonitis (RP) in locally advanced non-small cell lung cancer (LANSCLC) patients treated with chemoradiotherapy. METHODS: Between March 2006 and April 2010, 57 LANSCLC patients were enrolled in a prospective study. Fusion of SPECT and computed tomography scans provides perfusion-weighted functional dose-volume histogram (DVH) and associated functional dosimetric parameters. Blood for serum biomarkers-interleukin-6 (IL-6), transforming growth factor-beta1, and superoxide dismutase (SOD)-was drawn pre-RT and then 40 Gy/4 weeks during the treatment. The incidence of RP was related to the functional and biologic metrics. The predictability of predictors was calculated and compared based on the area under receiver-operating characteristic (ROC) curve (AUC). RESULTS: Relative volumes of functional lung receiving more than a threshold dose of 5-50 Gy at increments of 5 Gy and elevated levels of serum SOD after delivery of 40 Gy/4 weeks were associated with RP (p < 0.05). The best predictive efficacy of SOD was observed for a cutoff value of 56 U/ml, with a sensitivity of 0.80 (95 % CI 0.28-0.99) and a specificity of 0.67 (95 % CI 0.43-0.65) (p = 0.040). Functional DVH provided better predictive outcome (AUC 0.76-0.98) than standard DVH (AUC 0.62-0.86) for patients with poor baseline lung function. CONCLUSION: Functional metrics were identified to be better predictors for RP in patients with poor baseline lung function. SOD seemed to be a potential predictor for RP; however, it will need to be further verified using a larger sample size.
OBJECTIVE: To study the predictive value of functional and biologic metrics for predicting radiation pneumonitis (RP) in locally advanced non-small cell lung cancer (LANSCLC) patients treated with chemoradiotherapy. METHODS: Between March 2006 and April 2010, 57 LANSCLC patients were enrolled in a prospective study. Fusion of SPECT and computed tomography scans provides perfusion-weighted functional dose-volume histogram (DVH) and associated functional dosimetric parameters. Blood for serum biomarkers-interleukin-6 (IL-6), transforming growth factor-beta1, and superoxide dismutase (SOD)-was drawn pre-RT and then 40 Gy/4 weeks during the treatment. The incidence of RP was related to the functional and biologic metrics. The predictability of predictors was calculated and compared based on the area under receiver-operating characteristic (ROC) curve (AUC). RESULTS: Relative volumes of functional lung receiving more than a threshold dose of 5-50 Gy at increments of 5 Gy and elevated levels of serum SOD after delivery of 40 Gy/4 weeks were associated with RP (p < 0.05). The best predictive efficacy of SOD was observed for a cutoff value of 56 U/ml, with a sensitivity of 0.80 (95 % CI 0.28-0.99) and a specificity of 0.67 (95 % CI 0.43-0.65) (p = 0.040). Functional DVH provided better predictive outcome (AUC 0.76-0.98) than standard DVH (AUC 0.62-0.86) for patients with poor baseline lung function. CONCLUSION: Functional metrics were identified to be better predictors for RP in patients with poor baseline lung function. SOD seemed to be a potential predictor for RP; however, it will need to be further verified using a larger sample size.
Authors: L B Marks; M T Munley; D P Spencer; G W Sherouse; G C Bentel; J Hoppenworth; M Chew; R J Jaszczak; R E Coleman; L R Prosnitz Journal: Int J Radiat Oncol Biol Phys Date: 1997-05-01 Impact factor: 7.038
Authors: Raymond H Mak; Brian M Alexander; Kofi Asomaning; Rebecca S Heist; Chen-yu Liu; Li Su; Rihong Zhai; Marek Ancukiewicz; Brian Napolitano; Andrzej Niemierko; Henning Willers; Noah C Choi; David C Christiani Journal: Cancer Date: 2011-12-05 Impact factor: 6.860
Authors: Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Zafer Kocak; Gerben R Borst; Jing Zeng; Sumin Zhou; Donna R Hollis; Junan Zhang; Elizabeth S Evans; Rodney J Folz; Terrence Wong; Daniel Kahn; Jose S A Belderbos; Joos V Lebesque; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2007-01-01 Impact factor: 7.038
Authors: L B Marks; D P Spencer; G W Sherouse; G Bentel; R Clough; K Vann; R Jaszczak; R E Coleman; L R Prosnitz Journal: Int J Radiat Oncol Biol Phys Date: 1995-08-30 Impact factor: 7.038
Authors: Alena Novakova-Jiresova; Mieke M Van Gameren; Rob P Coppes; Harm H Kampinga; Harry J M Groen Journal: Radiother Oncol Date: 2004-05 Impact factor: 6.280
Authors: Lujun Zhao; Kerby Sheldon; Ming Chen; Moli S Yin; James A Hayman; Gregory P Kalemkerian; Doug Arenberg; Susan E Lyons; Jeffrey L Curtis; Mary Davis; Kemp B Cease; Dean Brenner; Mitchell S Anscher; Theodore S Lawrence; Feng Ming Kong Journal: Lung Cancer Date: 2007-10-01 Impact factor: 5.705
Authors: Claudia E Rübe; Jan Palm; Michael Erren; Jochen Fleckenstein; Jochem König; Klaus Remberger; Christian Rübe Journal: PLoS One Date: 2008-08-06 Impact factor: 3.240
Authors: Mohammed Alharbi; Stefan Janssen; Heiko Golpon; Michael Bremer; Christoph Henkenberens Journal: Radiat Oncol Date: 2017-11-02 Impact factor: 3.481
Authors: L Torre-Bouscoulet; W R Muñoz-Montaño; D Martínez-Briseño; F J Lozano-Ruiz; R Fernández-Plata; J A Beck-Magaña; C García-Sancho; A Guzmán-Barragán; E Vergara; M Blake-Cerda; L Gochicoa-Rangel; F Maldonado; M Arroyo-Hernández; O Arrieta Journal: Respir Res Date: 2018-04-24